Toremifene citrate

CAS No. 89778-27-8

Toremifene citrate( GTx-006 | NK 622 | NSC 613680 )

Catalog No. M16457 CAS No. 89778-27-8

Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 29 In Stock
25MG 37 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Toremifene citrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.
  • Description
    Toremifene Citrate(NK 622; FC 1157a) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis.(In Vitro):Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis and other adverse effects resulting from ADT with prostate cancer.The growth of Ac-1 cells was inhibited by tamoxifen, toremifene and atamestane in vitro with IC50values of 1.8±1.3μM, 1±0.3μM and 60.4±17.2μM, respectively. The combination of toremifene plusatamestane was found to be better than toremifene or atamestane alone in vitro.(In Vivo):The effect of this combination was then studied in vivo using Ac-1 xenografts grown in ovariectomized female SCID mice. The mice were injected with toremifene (1000μg/day), atamestane (1000μg/day), tamoxifen (100μg/day), or the combination of toremifene plus atamestane. In this study, our results indicate that the combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone.
  • In Vitro
    Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis and other adverse effects resulting from ADT with prostate cancer. The growth of Ac-1 cells was inhibited by tamoxifen, toremifene and atamestane in vitro with IC50values of 1.8±1.3μM, 1±0.3μM and 60.4±17.2μM, respectively. The combination of toremifene plusatamestane was found to be better than toremifene or atamestane alone in vitro.
  • In Vivo
    The effect of this combination was then studied in vivo using Ac-1 xenografts grown in ovariectomized female SCID mice. The mice were injected with toremifene (1000μg/day), atamestane (1000μg/day), tamoxifen (100μg/day), or the combination of toremifene plus atamestane. In this study, our results indicate that the combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone.
  • Synonyms
    GTx-006 | NK 622 | NSC 613680
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    89778-27-8
  • Formula Weight
    598.08
  • Molecular Formula
    C32H36ClNO8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 100 mg/mL (167.2 mM)
  • SMILES
    CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Locci P, et al. J Interferon Cytokine Res. 2001 Nov;21(11):961-70.
molnova catalog
related products
  • Oxibendazole

    Oxibendazole is a benzimidazole drug that interferes with metabolic pathways, used to protect against roundworms, strongyles, threadworms, pinworms and lungworm infestations in horses and some domestic pets.

  • Mestranol

    Mestranol is the 3-methyl ether of ethinylestradiol. It was the estrogen used in many of the first oral contraceptives.

  • GDC-0927

    GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.